Euro Dementia 2025, Dementia Conference, Neuro-inflammation, Cognitive Neuroscience, Memory Disorders, Cognitive Rehabilitation, Neuroplasticity and Alzheimer’s Diseases, Lewy Body Dementia, Neurodegenerative Diseases, Genetics of Alzheimer’s, Cognitive Behavioural Therapy

Recommended Global Neuroscience Webinars & Conferences

Europe & UK

Neuroscience 2025, France Spine 2025, Italy Dementia Congress 2025, Netherlands Neuroscience Congress-2025, France NEUROSCIENCE_2025, France

Asia Pacific & Middle East

Neuroscience-2025, UAE

Canada

Brain Disorders-2025, USA Neuroscience Congress 2025, Canada Neurogenetics 2025, Canada Stroke Summit 2025, Canada

Euro Dementia 2025

About Conference

We welcome all the participants around the globe to attend the “19^th International Conference on Dementia and Alzheimer Disease” is scheduled on June 16-17, 2025 in Frankfurt, Germany which aims to expanding networking opportunities and the conference will feature cutting-edge presentations, engaging panel discussions, and increased interaction with industry leaders and specialists.

Euro Dementia 2025 aims to foster the exchange of groundbreaking ideas and innovations among experts, industry leaders, and researchers in the fields of psychology, academia, and clinical studies. We have carefully crafted a diverse program that caters to your interests and provides numerous opportunities to network with international colleagues.

We look forward to welcoming you to an event that promises to inspire collaboration, foster new ideas, and advance the field of dementia and Alzheimer’s disease research.

Can Dementia Be Cured?

Discovering the friend or family member has Alzheimer's or other types of dementia is scary. One of the most primary inquiry that arise is whether there is a cure or a way to recover from the condition. However, it's important to note that not all memory loss is due to Alzheimer's or dementia. Other factors, such as thyroid imbalances, stress, vitamin deficiencies, or certain medications, can also contribute to memory issues.

Currently, there is no cure for dementia. The condition is caused by a variety of underlying diseases, which makes it unlikely that a single cure will emerge. Both dementia and Alzheimer’s disease represent some of the most significant public health challenges of our time. Globally, at least 44 million people are living with dementia, and this number is expected to double by 2030 and potentially triple by 2050, reaching 115 million. A large portion of this increase is expected to occur in developing regions, including Western Europe and North America. In fact, 62% of individuals with dementia currently live in developing countries.

Today, over 35 million people worldwide are affected by dementia. While there are no treatments available to halt or reverse the brain damage caused by Alzheimer's disease, certain medications may temporarily alleviate some symptoms for some individuals. In Canada, it is estimated that by 2040, 1.4 million Canadians will be living with dementia, costing the economy nearly $300 billion annually. On a global scale, the economic burden of dementia is estimated to be $600 billion per year.

Why Attend Euro Dementia 2025?

Euro Dementia 2025 offers a unique platform for researchers, healthcare professionals, and industry leaders to share innovative research and explore new developments in the understanding and treatment of Alzheimer's and other dementias. This conference will bring together leading experts, neurologists, and dementia researchers from both academia and the healthcare industry to present their latest findings and discuss potential breakthroughs. The event will feature sessions led by world-class specialists in neurology, providing valuable insights into the most current research and promising advancements in the field.

Target Audience:

Neurologists
Gerontologists and Geriatricians
Neuroscientists
Specialists
Researchers
Pharmaceutical and Biotechnology Industry Professionals
Health care professionals
Professors
Industrial Experts
Neurosurgeons
Psychiatrist
Nutritional Scientists
Lecturers and Students from Academia in the study of Dementia

Session and Tracks

Track 1: Alzheimer’s disease

Alzheimer’s disease is a progressive neurodegenerative disorder that primarily affects memory, thinking, and behavior. It is the most common cause of dementia. It is characterized by the accumulation of amyloid plaques and tau tangles in the brain, leading to the death of brain cells. Risk factors include age, genetics, and lifestyle factors. While there is no cure, treatments aim to manage symptoms and slow progression. Alzheimer's is a growing global health challenge, with an estimated 44 million people affected worldwide, a number expected to double by 2050. Early diagnosis and ongoing research are crucial for improving patient outcomes.

European Societies: Alzheimer’s disease International; Alzheimer's Europe; European Federation of Neurological Societies; European Alzheimer's Association; Dementia Services Development Centre; International Alzheimer’s Disease Society; Society for Research on Alzheimer’s Disease; The European Association of Geriatric Psychiatry; European Brain Council; European Society of Clinical Neurophysiology

USA Societies: Alzheimer's Association; Alzheimer’s Disease Neuroimaging Initiative; National Institute on Aging; American Alzheimer's Association of Geriatric Psychiatry; Alzheimer's Foundation of America; Society for Neuroscience; American Geriatrics Society; Cure Alzheimer's Fund; National Alzheimer’s Project Act; The Lewy Body Dementia Association

Asian Societies: Japan Society of Dementia Research; Korea Dementia Society; Chinese Alzheimer's Disease and Dementia Society; Indian Alzheimer’s and Related Disorders Society; Taiwan Alzheimer’s Disease Association; Alzheimer's Malaysia; Hong Kong Alzheimer's Disease Association; Singapore Alzheimer’s Disease Association; Bangladesh Alzheimer’s Foundation

Track 2: Vascular Dementia

Vascular Dementia is the second most common type of dementia, caused by reduced blood flow to the brain due to damage to blood vessels. This disruption in circulation leads to brain cell death, affecting cognitive function, memory, and decision-making. Vascular dementia often results from strokes, either major or mini (transient ischemic attacks), or from other conditions that damage the blood vessels, such as high blood pressure, diabetes, and high cholesterol.

Symptoms of vascular dementia can vary but commonly include memory loss, confusion, difficulty concentrating, and problems with planning or organizing tasks. Unlike Alzheimer's, vascular dementia symptoms may appear suddenly, often following a stroke or series of strokes.

Track 3: Parkinson’s Diseases and Dementia

Parkinson’s disease (PD) is a neurodegenerative disorder that primarily affects movement, causing tremors, stiffness, and difficulty with balance and coordination. Over time, some individuals with Parkinson's may develop Parkinson’s disease dementia (PDD), a form of dementia that affects cognitive function, including memory, attention, and executive function. The progression of Parkinson's disease can lead to changes in the brain's dopamine systems, which can also impact areas responsible for cognition. Symptoms of PDD include memory loss, difficulty with problem-solving, and personality changes.

Track 4: Pathophysiology of Dementia

The pathophysiology of dementia involves the progressive degeneration of brain cells, leading to impaired cognitive function. In Alzheimer's disease, the most common cause of dementia, amyloid plaques (abnormal protein clumps) and tau tangles (twisted protein fibers) disrupt communication between neurons, causing cell death. In vascular dementia, reduced blood flow due to damaged blood vessels results in brain cell death, often following strokes. Other types, like Parkinson’s disease dementia, involve the loss of dopamine-producing neurons, affecting both movement and cognition.

The underlying pathophysiological changes in dementia often lead to a decline in memory, judgment, reasoning, and the ability to perform daily tasks. These neurodegenerative processes are still not fully understood, and ongoing research aims to identify mechanisms for early diagnosis and treatment.

Track 5: Dementia and Nutrition: The Role of Diet in Cognitive Health

Dementia and Nutrition are closely linked, as a healthy diet can support brain function and potentially reduce the risk of cognitive decline. Diets rich in antioxidants, omega-3 fatty acids, and anti-inflammatory nutrients have been shown to benefit brain health. For example, the Mediterranean diet, which includes fruits, vegetables, whole grains, healthy fats, and fish, has been associated with a lower risk of dementia. Similarly, diets high in vitamins such as B12, D, and folate are crucial for cognitive function. Conversely, diets high in processed foods, sugars, and unhealthy fats may contribute to neuroinflammation and vascular damage, which can accelerate cognitive decline. Proper nutrition, along with regular physical activity, is essential for maintaining brain health and potentially delaying the onset of dementia.

Track 6: Alzheimer's Diseases Therapeutics

Alzheimer's disease therapeutics focus on managing symptoms and slowing disease progression, though there is no cure. Current treatments include acetylcholinesterase inhibitors (e.g., donepezil) to improve neurotransmission and temporarily alleviate cognitive symptoms. NMDA antagonists (e.g., memantine) help regulate glutamate activity, which is involved in learning and memory. Recent advancements include monoclonal antibodies targeting amyloid plaques (e.g., aducanumab), aimed at reducing the buildup of toxic proteins in the brain. Research is also exploring gene therapy, anti-inflammatory treatments, and lifestyle interventions to prevent or delay the onset. Early diagnosis and personalized care are key to optimizing therapeutic outcomes.

Track 7: Neuro-inflammation and the Immune System in Dementia

Neuro-inflammation plays a critical role in the development and progression of dementia, including Alzheimer’s disease. Inflammation in the brain is often triggered by the accumulation of amyloid plaques and tau tangles, which activate the immune system’s microglia and astrocytes. While these cells initially protect the brain, chronic activation leads to neuroinflammation, causing neuronal damage and impairing cognitive function.

The immune response in dementia also involves the disruption of the blood-brain barrier and increased release of pro-inflammatory cytokines. Targeting neuroinflammation is a promising area of research, with potential therapies aimed at modulating the immune system to slow disease progression and improve brain health.

Track 8: Geriatrics and Dementia Care

Geriatrics and dementia care focus on supporting older adults with cognitive decline, addressing both medical and emotional needs. Care involves managing chronic conditions, optimizing medications, and ensuring patient safety. It also includes cognitive stimulation, behavioral management, and providing caregiver support. The aim is to improve quality of life through a holistic approach, considering both physical and mental health, while assisting families in navigating the challenges of caregiving for individuals with dementia.

Track 9: Alzheimer’s Diseases and Co-Morbidities

Alzheimer's disease and co-morbidities often occur together, complicating diagnosis and treatment. Common co-existing conditions include cardiovascular diseases, diabetes, depression, and stroke, which can worsen cognitive decline. For instance, hypertension and diabetes contribute to vascular damage, increasing Alzheimer's risk. Depression and sleep disorders are also prevalent, affecting mood and cognitive function. Other conditions like Parkinson’s disease and nutritional deficiencies can further impair memory and daily functioning.

Track 10: Memory Disorders and Cognitive Dysfunction

Memory disorders and cognitive dysfunction refer to impairments in memory, thinking, and problem-solving abilities. These conditions can result from various causes, including Alzheimer's disease, vascular dementia, Parkinson's disease, and traumatic brain injury. Memory issues can range from mild forgetfulness to severe cognitive decline, affecting daily functioning. Cognitive dysfunction may include difficulties with attention, decision-making, and language. Early detection and intervention are essential for managing these disorders, often involving a combination of medications, cognitive therapies, and lifestyle changes to improve cognitive function and quality of life.

Track 11: Dementia and Diabetes

Dementia and diabetes are closely linked, with diabetes increasing the risk of cognitive decline and dementia. High blood sugar levels can damage blood vessels, leading to vascular dementia, while insulin resistance may contribute to Alzheimer’s disease by impairing brain function. Managing diabetes through diet, exercise, and medication is crucial to reduce the risk of cognitive deterioration.

Track 12: Neuroimaging in Dementia

Neuroimaging in dementia plays a crucial role in diagnosing and monitoring neurodegenerative diseases. Techniques such as MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) scans help identify structural brain changes, including atrophy and lesions. Advanced imaging methods like PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) can detect abnormal protein deposits, such as amyloid plaques in Alzheimer's disease. Neuroimaging aids in early diagnosis, differentiating between types of dementia, and tracking disease progression for better treatment planning.

Track 13: Childhood Trauma and Dementia

Childhood trauma has been linked to an increased risk of developing dementia in later life. Adverse experiences such as abuse, neglect, or prolonged stress can affect brain development, leading to long-term changes in brain structure and function. Chronic stress from trauma may contribute to neuroinflammation and cognitive decline, raising the likelihood of neurodegenerative diseases like Alzheimer's. These early life experiences can significantly impact brain health and dementia risk in adulthood.

Track 14: Early Diagnosis and Biomarkers in Dementia

Early diagnosis of dementia is crucial for effective intervention and slowing disease progression. Advances in biomarkers—biological indicators of disease—are enhancing diagnostic accuracy and enabling earlier detection. Biomarkers for dementia include amyloid plaques and tau protein tangles in Alzheimer's disease, detectable through PET scans or cerebrospinal fluid analysis. Additionally, genetic markers, neuroimaging (MRI, fMRI), and blood-based tests are being researched for their potential to identify dementia at its earliest stages. Early detection allows for timely treatment, better management of symptoms, and improved outcomes for patients and caregivers.

Track 15: Clinical features and Physiotherapy for dementia

Clinical features of dementia include memory loss, confusion, and difficulty with communication, impaired judgment, and changes in mood or behavior. As dementia progresses, individuals may struggle with daily tasks, mobility, and coordination. Physiotherapy plays a key role in managing these symptoms by improving physical function, enhancing mobility, and reducing the risk of falls. Tailored exercise programs can help maintain strength, balance, and flexibility, while promoting overall well-being and improving the quality of life for dementia patients.

Track 16: Medical Biotechnology and Alzheimer’s Diseases

Medical biotechnology is playing an increasingly vital role in the understanding and treatment of Alzheimer’s disease. Innovations in biotechnology have led to the development of biomarkers for early diagnosis, including blood tests and imaging techniques that detect amyloid plaques and tau tangles. Advances in gene therapy and stem cell research hold promise for potentially reversing or halting disease progression. Additionally, biotechnological breakthroughs in targeted drug development, such as monoclonal antibodies (e.g., aducanumab), aim to reduce amyloid buildup in the brain. These innovations offer hope for more effective treatments and better outcomes for Alzheimer's patients.

Track 17: Amyloid Protein in Dementia

Amyloid protein accumulation is a hallmark of Alzheimer's disease and other forms of dementia. The buildup of amyloid plaques between neurons disrupts cell communication, leading to neurodegeneration and cognitive decline. Amyloid-related changes are central to the disease’s pathophysiology, making it a key target for diagnostic biomarkers and therapeutic strategies aimed at slowing or halting disease progression.

Track 18: Ageing & Dementia

Ageing is the primary risk factor for dementia, with the likelihood of developing neurodegenerative diseases like Alzheimer's increasing with age. As the brain ages, it undergoes changes in structure and function, including the buildup of amyloid plaques and tau tangles. These changes can impair cognitive function, leading to memory loss, confusion, and other symptoms of dementia. The growing aging population worldwide makes dementia a major public health challenge, emphasizing the need for early detection, prevention strategies, and effective care solutions.

Track 19: Genomic Medicine in Alzheimer’s disease

Genomic medicine in Alzheimer's disease explores the role of genetic factors in the development and progression of the disease. Research has identified several genes linked to Alzheimer's, such as APOE4, which increases the risk, and APP, PSEN1, and PSEN2 genes, which are associated with early-onset forms of the disease. Advances in genomic technologies, including whole-genome sequencing and gene editing, are paving the way for personalized treatments and early diagnosis. By understanding genetic risk factors, genomic medicine holds promise for identifying individuals at risk, developing targeted therapies, and potentially preventing or slowing Alzheimer's disease progression.

Track 20: Neuropathology of Alzheimer's disease

The neuropathology of Alzheimer's disease is characterized by the accumulation of amyloid plaques and neurofibrillary tau tangles in the brain. These abnormal protein deposits disrupt neuronal communication, trigger inflammation, and cause neuronal death. Over time, this leads to brain atrophy, memory loss, and cognitive decline, which are hallmark features of the disease.

Track 21: Pharmacological Advances in Dementia Treatment

Pharmacological advances in dementia treatment focus on developing drugs to slow disease progression and manage symptoms. Current medications for Alzheimer’s disease, such as acetylcholinesterase inhibitors (e.g., donepezil) and NMDA antagonists (e.g., memantine), help improve cognitive function temporarily. Recent breakthroughs include monoclonal antibodies, like aducanumab, which target amyloid plaques to reduce protein buildup in the brain. Other promising areas of research involve tau-targeted therapies, anti-inflammatory drugs, and gene therapies. These innovations aim to address the underlying causes of dementia, offering hope for more effective treatments and, eventually, potential disease-modifying options.

Past Conference Report

Conference series LLC takes a great honor in announcing the commencement of the “18^th International Conference on Dementia and Alzheimer’s disease” held on June 12-13, 2023 in Edinburgh, Scotland. Euro Dementia 2023 received an overwhelmingly positive response from across the globe, and the conference was a resounding success in advancing the understanding of neuroscience and the latest developments in dementia and Alzheimer’s disease research.

The event, organized under the theme “Advancements and Breakthroughs in Dementia Research and Development,” brought together a diverse community of researchers, clinicians, business leaders, and students to engage in meaningful discussions. The conference aimed to foster the exchange of cutting-edge ideas and promote the application of new insights in the field of neurology. It provided an invaluable platform for strengthening collaborations that will drive further scientific progress in dementia care and research.

This distinguished gathering featured notable scientists, neurologists, neuroscientists, healthcare professionals, and esteemed university professors who shared their knowledge and expertise on critical issues facing the field of neuroscience. The conference not only offered deep insights into the latest research but also allowed for an open and stimulating exchange of ideas and experiences.

Attendees were privileged to hear from world-renowned experts, including Don Kulasiri (Lincoln University, New Zealand), V.R. Badrakalimuthu (Parklands Hospital, UK), Manabu Tamura (Ministry of Economy, Trade and Industry, Japan), Arturo Solís Herrera (Human Photosynthesis Research Centre, Mexico), Li Zeng (National Neuroscience Institute, Singapore), Nedim Ongun (Burdur State Hospital, Turkey), Ying Wang (China Pharmaceutical University, China), Mario Durán-Prado (University of Castilla-La Mancha, Spain), and Santosh Bangar (MIND Clinic for Senior Citizens, India). These eminent speakers provided invaluable insights into the latest breakthroughs in the fields of dementia and Alzheimer’s research.

We extend our deepest gratitude to the Organizing Committee Members, Chairs, Co-Chairs, Speakers, Students, Media Partners, and Editorial Board Members of the Journal of Alzheimer’s Disease & Parkinsonism, Journal of Neurology & Neurophysiology, and Journal of Neurology and Neuroscience for their unwavering support and contribution to the success of the conference.

The tremendous response to Euro Dementia 2023 inspires us to continue organizing such impactful events, dedicated to advancing neuroscience research. With this in mind, we are thrilled to announce the “19^th International Conference on Dementia and Alzheimer’s disease” scheduled for June 16-17, 2025 in Frankfurt, Germany. We look forward to welcoming you to this next pivotal gathering in the ongoing pursuit of breakthroughs in dementia and Alzheimer’s research.

We hope to see you there!

Market Analysis

Dementia is a general term that encompasses a group of symptoms, including decline in mental capacity, judgment, language, complex motor skills, and other intellectual functions, which are caused by brain damage resulting from cerebrovascular issues, neuronal death, or brain injury. Dementia can be triggered by various factors, such as drug abuse, alcoholism, brain injuries, medication side effects, thyroid abnormalities, and vitamin B12 deficiencies.

Dementia, including Alzheimer’s disease, represents one of the largest global public health challenges of our time. Vascular dementia, the second most common form, arises from brain damage and is a significant contributor to the global dementia burden.

Recent reports indicate that the market for Alzheimer's disease (AD) treatments is expanding, driven by the development of new therapeutic methods and the rising incidence of the disease. The increasing prevalence of Alzheimer's is largely due to the growing number of individuals over the age of 65, with Alzheimer’s disease estimated to affect up to 6% of the population in this age group. Additionally, although rare, instances of young-onset Alzheimer's, affecting individuals under 65, have been reported.

The global market for Alzheimer's disease reached $10.2 billion in 2012 and continues to grow. The market for Alzheimer’s disease therapeutics and diagnostics is projected to exceed $6.2 billion by 2020, up from $4.4 billion in 2015, with a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020. As of 2023, the Alzheimer's therapeutics market has further expanded, with projections indicating a continued upward trajectory due to ongoing research breakthroughs and an aging population.

Studies from 2023 and 2024 suggest that Alzheimer's diagnostic methods, including a wide range of tests such as esoteric, public health, genomic, and anatomic technologies, are advancing rapidly. Global market trends indicate that new technologies, including mass spectrometry and other novel diagnostic tools, are gaining traction. The global market for laboratory-developed tests (LDTs), which includes many Alzheimer’s-related diagnostics, reached approximately $9.7 billion in 2015 and is expected to grow significantly in the coming years. By 2024, the laboratory testing market is projected to exceed $12.5 billion, continuing to rise to $14.9 billion by 2026, with a CAGR of 6.3% from 2016 to 2026.

These figures highlight a robust market for both Alzheimer’s therapeutics and diagnostics, underscoring the growing need for improved treatment options and early detection solutions, driven by the increasing incidence of dementia and Alzheimer's disease worldwide.

To Collaborate Scientific Professionals around the World

Conference Date June 16-17, 2025

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Poster Opportunity E-Poster Opportunity

Useful Links

Past Conference Report

Euro Dementia 2023 Conference

Supported By

Journal of Neurology and Neuroscience Journal of Brain and Neurology Journal of Alzheimers Disease & Parkinsonism

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by

Dementia and Alzheimer Disease

June 16-17, 2025 Frankfurt, Germany

Neurological Advancements: Revolutionizing Alzheimer's Diagnosis and Treatment

Euro Dementia 2025 | Dementia Research Conference | Alzheimer’s Conference | Neurodegenerative Disorders | Alzheimer's Diseases | Memory Disorders | Dementia Prevention | Neuro-inflammation | Cognitive Behavioral Therapy | Frankfurt | Germany | Conference Series

Conference Series Conferences gaining more Readers and Visitors

Recommended Global Neuroscience Webinars & Conferences

Europe & UK

Asia Pacific & Middle East

Canada

Euro Dementia 2025

About Conference

Session and Tracks

Past Conference Report

Market Analysis

To Collaborate Scientific Professionals around the World

Useful Links

Past Conference Report

Supported By

Keytopics